ストックスクリーナーアプリを入手
30.65
5.25%
1.53
アフターアワーズ：
30.41
-0.24
-0.78%
前日終値:
$29.12
開ける：
$29.04
24時間の取引高:
1.72M
Relative Volume:
0.90
時価総額：
$4.13B
収益：
-
当期純損益:
$-507.65M
株価収益率:
-6.663
EPS:
-4.6
ネットキャッシュフロー:
$-616.24M
1週間 パフォーマンス:
+9.31%
1か月 パフォーマンス:
-59.26%
6か月 パフォーマンス:
-73.49%
1年 パフォーマンス:
-50.91%
1日の値動き範囲:
$28.75
$30.68
1週間の範囲:
$27.80
$32.72
52週間の値動き範囲:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
30.65 | 4.13B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
When the Price of (PCVX) Talks, People Listen - news.stocktradersdaily.com
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - MSN
Vaxcyte Stock Plummets: What’s Next? - timothysykes.com
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential - Insider Monkey
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges By Investing.com - Investing.com South Africa
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges - Investing.com India
Vaxcyte (NASDAQ:PCVX) Price Target Lowered to $137.00 at Bank of America - MarketBeat
InvestingPro Fair Value model correctly predicted Vaxcyte’s decline By Investing.com - Investing.com UK
Vaxcyte (NASDAQ:PCVX) Given New $137.00 Price Target at Bank of America - Defense World
(PCVX) Investment Analysis - news.stocktradersdaily.com
Vaxcyte (PCVX) Stock Falls 45% Despite Positive Vaccine Trial Re - GuruFocus
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI - Yahoo Finance
BofA lowers Vaxcyte price target, says selloff after infant data ‘overdone’ - TipRanks
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Vaxcyte stock sinks despite Phase II IPD vaccine trial success - Yahoo Finance
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Vaxcyte’s Promising Vaccine Potential and Market Expansion Drive Buy Rating - TipRanks
Goldman Sachs cuts Vaxcyte stock price target to $100 - Investing.com
Goldman Sachs cuts Vaxcyte stock price target to $100 By Investing.com - Investing.com UK
Vaxcyte’s Strong Phase 2 Data and Future Prospects Justify Buy Rating Despite Market Overreaction - TipRanks
Vaxcyte price target lowered to $90 from $140 at Needham - MSN
Vaxcyte sights set on next results after ‘big moment’ with PCV - BioWorld MedTech
Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (NASDAQ:PCVX) - Seeking Alpha
Sector Update: Health Care Stocks Higher Late Afternoon - MarketScreener
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (NASDAQ:PCVX) - Seeking Alpha
Jefferies maintains Buy on Vaxcyte stock, price target at $146 By Investing.com - Investing.com Canada
Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns - TipRanks
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials - TipRanks
Vaxcyte falls as pneumococcal vaccine data fails to meet lofty investor expectations - TradingView
Jefferies maintains Buy on Vaxcyte stock, price target at $146 - Investing.com India
Daily Digest: Large Asian grocer T&T Supermarket to land in S.F.; Vaxcyte stock plunges - The Business Journals
Biotech Stocks Hammered After A Key FDA Official Resigns - Investor's Business Daily
Vaxcyte stock touches 52-week low at $33.19 amid market shifts - Investing.com
Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says - MarketScreener
Guggenheim maintains Vaxcyte stock Buy rating, $160 target By Investing.com - Investing.com Canada
Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study - TipRanks
Vaxcyte plunges despite pneumonia shot results as Marks departure weighs (PCVX:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Fall Pre-Bell Monday - MarketScreener
Vaxcyte’s VAX-24 shows promise in infant vaccine study By Investing.com - Investing.com South Africa
Vaxcyte Announces Positive Phase 2 Results for VAX-24 - TipRanks
Guggenheim maintains Vaxcyte stock Buy rating, $160 target - Investing.com
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine - Benzinga
S&P 500 Futures Fall in Premarket Trading; Vaxcyte, Moderna Lag - Barron's
Vaxcyte's Pneumococcal Conjugate Vaccine Candidate Shows Substantial Immune Response in Infants - Marketscreener.com
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - The Manila Times
Vaxcyte stock tumbles following Phase 2 study results By Investing.com - Investing.com Australia
Vaxcyte Announces Positive Topline Results From VAX-24 Infant Phase 2 Dose-Finding Study - MarketScreener
Vaxcyte stock tumbles following Phase 2 study results - Investing.com
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):